MX2018012739A - Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. - Google Patents

Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Info

Publication number
MX2018012739A
MX2018012739A MX2018012739A MX2018012739A MX2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A
Authority
MX
Mexico
Prior art keywords
cognitive function
leucine
acetyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2018012739A
Other languages
English (en)
Inventor
Factor Mallory
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2018012739A publication Critical patent/MX2018012739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción está dirigida a acetilleucina o una sal farmacéuticamente aceptable de la misma para usarse en la mejora de la función cognitiva, movilidad o función cognitiva y movilidad en un sujeto, por ejemplo, en un sujeto anciano.
MX2018012739A 2016-04-19 2017-04-19 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. MX2018012739A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (1)

Publication Number Publication Date
MX2018012739A true MX2018012739A (es) 2019-06-17

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012739A MX2018012739A (es) 2016-04-19 2017-04-19 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Country Status (14)

Country Link
US (2) US10905670B2 (es)
EP (1) EP3445351A1 (es)
JP (2) JP7387264B2 (es)
KR (4) KR20240018683A (es)
CN (1) CN109069463A (es)
AU (2) AU2017252507B2 (es)
BR (1) BR112018071547A2 (es)
CA (1) CA3021155A1 (es)
IL (3) IL310508A (es)
MX (2) MX2018012739A (es)
RU (2) RU2021107001A (es)
SG (2) SG10202106190RA (es)
WO (1) WO2017182802A1 (es)
ZA (1) ZA201806849B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
KR20210111757A (ko) * 2018-12-06 2021-09-13 인트라바이오 리미티드 아세틸-류신의 중수소화된 유사체
WO2020178721A1 (en) * 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers

Also Published As

Publication number Publication date
KR102413754B1 (ko) 2022-06-27
KR20220038814A (ko) 2022-03-29
ZA201806849B (en) 2019-07-31
US20210106548A1 (en) 2021-04-15
SG10202106190RA (en) 2021-07-29
US20230346732A1 (en) 2023-11-02
IL262379B (en) 2022-07-01
RU2018140131A3 (es) 2020-05-14
RU2018140131A (ru) 2020-05-14
JP7387264B2 (ja) 2023-11-28
RU2745912C2 (ru) 2021-04-02
IL262379A (en) 2018-11-29
IL293266A (en) 2022-07-01
IL293266B1 (en) 2024-03-01
US10905670B2 (en) 2021-02-02
AU2022256077A1 (en) 2022-11-17
JP2022024058A (ja) 2022-02-08
KR20220093386A (ko) 2022-07-05
KR20180134398A (ko) 2018-12-18
IL310508A (en) 2024-03-01
AU2017252507A1 (en) 2018-11-08
SG11201809031XA (en) 2018-11-29
US20190083438A1 (en) 2019-03-21
KR20240018683A (ko) 2024-02-13
MX2021014844A (es) 2022-01-18
WO2017182802A1 (en) 2017-10-26
CN109069463A (zh) 2018-12-21
EP3445351A1 (en) 2019-02-27
JP2019513814A (ja) 2019-05-30
BR112018071547A2 (pt) 2019-03-06
KR102632670B1 (ko) 2024-02-01
CA3021155A1 (en) 2017-10-26
AU2017252507B2 (en) 2022-07-21
RU2021107001A (ru) 2021-04-12

Similar Documents

Publication Publication Date Title
MX2019012534A (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
PH12015502788A1 (en) Antibody formulations and methods
CA160630S (en) Body groomer
TWD167562S (zh) 眼鏡
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
SG10201907901XA (en) Antibodies, uses & methods
EP3173089A4 (en) Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction
MX2021014844A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
IL271728A (en) Materials, uses and treatment methods
MX2017016096A (es) Agente antihipertensivo.
IL280191A (en) Dissolved dosages, methods and use
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
SG11201912827TA (en) 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2019005504A (es) Potenciadores de bmp.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
IN2013MU02813A (es)
TWD176882S (zh) 按摩裝置
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
UA98069U (xx) N-(3-ТРИФТОРМЕТИЛФЕНІЛ)-2-(2-ОКСО-3,5a,6,11b-ТЕТРАГІДРО-2Н,5Н-ХРОМЕНО[4',3':4,5]ТІОПІРАНО[2,3-d][1,3]ТІАЗОЛ-3-ІЛ)АЦЕТАМІД, ЩО ПРОЯВЛЯЄ АНАБОЛІЧНУ ТА АНДРОГЕННУ ДІЮ
UA92247U (ru) ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА
AU365961S (en) Clasp